For UK Healthcare Professionals Only
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.

For more information about products within the Pathway Portfolio, please click here for prescribing information

Cardiology

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

  • A full range of strengths available1
  • A first strength to market1
  • Simpler dosing which may help some patients with concordance and compliance1-2
  • The first brand to market1

All of which create a wider offering to patients.

Pathway to Partnership:

Trusted Brands:

  • Bioequivalent to brand originators3
  • Available from mainline wholesalers

Bespoke Support:

  • Price guarantee
  • Individualised rebates on request
Contact a member of our team

Please click here for Delofine® XL prescribing information

Delofine® XL (felodipine) prolonged-release tablets

Indicated for the treatment of hypertension and stable angina pectoris4.

  • Delofine® XL is bioequivalent to Plendil® XL across all strengths3

  • 3 strengths available 2.5mg, 5mg and 10mg4

  • Available as a 28-day pack1

CONTACT US TO REQUEST
A COST SAVING REPORT

The most cost-effective, full range of felodipine prolonged-release tablets, saving up to 59% on the UK Drug Tariffs1.

Delofine® XL could reduce the average ICS/ICB prescribing costs of felodipine prolonged release tablets by an average of £97,688 per annum, saving up to £3.5 million annually across the NHS5*.

References:

*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 36 ICS/ICB’s

  1. UK Drug Tariff (Accessed June 2026)
  2. Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
  3. Data on file, 10103111700 v 2.0 October 2024 Bioequivalence data
  4. Delofine® XL SmPC (Accessed June 2026)
  5. MAT-UK-EPI-0139-1 Pathway Portfolio cost savings, GPPLPD Date Range: Jan-26 – Mar-26

MAT-UK-XLP-0034-1 | June 2026